For the quarter ending 2025-09-30, IART had $14,272K increase in cash & cash equivalents over the period. $25,750K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,404 | -509,366 |
| Depreciation and amortization | 38,522 | 74,880 |
| Non-cash impairment charges | 0 | 511,365 |
| Deferred income tax benefit | -8,653 | -46,663 |
| Share-based compensation | 5,580 | 7,165 |
| Amortization of debt issuance costs and expenses associated with debt refinancing | 1,315 | 3,275 |
| Non-cash lease expense | -307 | -599 |
| Loss on disposal of property and equipment | 4 | -494 |
| Change in fair value of contingent consideration and others | -14,441 | -203 |
| Accounts receivable | -22,507 | 6,540 |
| Inventories | 23,345 | 20,074 |
| Prepaid expenses and other current assets | -16,222 | 21,216 |
| Other non-current assets | -1,001 | -2,334 |
| Accounts payable, accrued expenses and other current liabilities | 5,782 | -2,078 |
| Contract liabilities | 371 | 2,344 |
| Other non-current liabilities | 1,760 | 2,544 |
| Net cash provided by operating activities | 40,906 | -2,338 |
| Purchases of property and equipment | 15,156 | 49,066 |
| Cash paid for business acquisitions, net of cash acquired | 0 | 0 |
| Purchases of short-term investments | 0 | 8,502 |
| Proceeds from maturities of short-term investments | 0 | - |
| Net payments from swaps designated as net investment hedges | 432 | - |
| Net cash used in investing activities | -15,588 | -57,568 |
| Proceeds from borrowings of long-term indebtedness | 603,700 | 67,300 |
| Payments on debt | 38,688 | 31,131 |
| Repayments of convertible debt | 574,983 | - |
| Payment of debt issuance costs | 75 | 3,855 |
| Purchases of treasury stock | 0 | 221 |
| Payments for contingent considerations | 0 | 16,451 |
| Proceeds from exercised stock options | 0 | 957 |
| Cash taxes paid in net equity settlement | 199 | 2,361 |
| Net cash provided by financing activities | -10,245 | 14,238 |
| Effect of exchange rate changes on cash and cash equivalents | -801 | 17,207 |
| Net decrease in cash and cash equivalents | 14,272 | -28,461 |
| Cash and cash equivalents at beginning of period | 246,375 | - |
| Cash and cash equivalents at end of period | 232,186 | - |
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)